FDA panel votes 3-14 that Abbott (ABT) has not found right Humira dose
Tweet Send to a FriendGet Alerts ABT Hot Sheet
Trade ABT Now!
FDA panel votes 3-14 that Abbott (NYSE: ABT) has not found right Humira dose.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Goldman Sachs Upgrades Abbott Labs (ABT) to Buy
- UPDATE: CBO Reverses Projection for U.S. Medicare Advantage Decline (HUM) (UNH)
- Medtronic (MDT) Receives CE Mark for Export Advance Catheter
Create E-mail Alert Related Categories
FDA, General News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
